MDGL Stock: Price, Earnings History and SEC Filings
Madrigal Pharmaceuticals, Inc. (MDGL) last traded at $430.36, down 0.31% on the latest session and down 14.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.99 against an analyst estimate of $-2.55, a beat of 22.0%.
$430.36 -0.31%
1 month-14.60%
52-week high$615.00
52-week low$399.00
Volume251,657
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
MDGL earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $-1.99 | $-2.55 | +21.96% |
| Mar 2026 | May 6, 2026 | $-3.25 | $-3.61 | +9.97% |
| Dec 2025 | Feb 19, 2026 | $-2.57 | $0.04 | -6525.00% |
| Sep 2025 | Nov 4, 2025 | $-5.08 | $-1.98 | -156.57% |
MDGL beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for MDGL
SEC filing data is not available right now. You can search for MDGL on SEC EDGAR.
MDGL news
- Inventiva (IVA) vs. CRSP and MDGL: Can Lanifibranor’s Phase 3 Trial Unlock 62% Upside?Oct 28, 2026 · finance.yahoo.com
- Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out forOct 28, 2026 · finance.yahoo.com
- Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should KnowOct 27, 2026 · finance.yahoo.com
- Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASHOct 27, 2026 · finance.yahoo.com
- Can Corcept Therapeutics Stock Rally 40% After This Dip?Oct 26, 2026 · trefis.com
- Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026Oct 20, 2026 · finance.yahoo.com
- BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA SaysOct 19, 2026 · finance.yahoo.com
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. (MDGL) is a US-listed public company on Nasdaq.